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Abstract
Background: The mechanisms of chemoresistance in ovarian cancer patients remain largely to be
elucidated. Paclitaxel/cisplatin combination is the standard chemotherapeutic treatment for this
disease, although some patients do not respond to therapy. Our goals were to investigate whether
TUBB mutations and mismatch repair defects underlie paclitaxel and cisplatin resistance.
Methods: Thirty-four patients with primary ovarian carcinomas (26 serous and eight clear cell
carcinomas) treated with paclitaxel/cisplatin were analysed. TUBB exon 4 was analysed by nested
PCR after a first round PCR using intronic primers. Microsatellite analysis was performed with the
quasimonomorphic markers BAT 26 and BAT 34.
Results: Twenty-two of the 34 ovarian cancers (64.7%) presented residual tumour after surgery,
seven of which (7/22; 31.8%) were shown to be chemoresistant (five serous and two clear cell
tumours). Sequence analysis did not find any mutation in TUBB exon 4. Microsatellite instability was
not detected in any of the ovarian carcinomas.
Conclusion: We conclude that TUBB exon 4 mutations and mismatch repair defects do not play
a significant role in paclitaxel/cisplatin resistance.
Background
Ovarian cancer is the fourth most common cancer in
women [1]. The standard treatment for ovarian cancer is
cytoreductive surgery followed by combination systemic
chemotherapy [2]. Since the middle 90's, the combina-
tion paclitaxel/cisplatin became the standard chemother-
apeutic treatment for poor prognosis ovarian cancer [3].
Nevertheless, some patients are resistant to this chemo-
therapeutic treatment, making it important to clarify the
underlying mechanisms of resistance [4].
Paclitaxel binds to microtubules and causes kinetic sup-
pression (stabilisation) of microtubule dynamics, pro-
moting their polymerisation and cell cycle arrest in
mitosis (antimitotic activity), which probably leads to
apoptosis [5,6]. Microtubules are composed of a dimeric
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protein, tubulin, with alpha (α) and beta (β) tubulin het-
erodimers in dynamic equilibrium. The β-tubulin gene
(TUBB), mapped to 6p21.3 [7], is composed of four exons
and encodes a 445-aminoacid protein with GTPase func-
tion to which paclitaxel preferentially binds [8]. Cisplatin
is activated intracellularly and establishes inter- and intra-
strand DNA adducts that block replication and transla-
tion. The fate of cells after cisplatin exposure depends
both on the extent of DNA damage and the cellular
response to it, and apoptosis can be induced as a conse-
quence [5,9]. Although the specific mechanism that trig-
gers apoptosis is not totally clear, some evidence suggests
that this process can be mediated by the DNA mismatch
repair system (MMR) [5,9].
Drug resistance is considered a multifactorial process, but
the detailed mechanisms are still unknown. Recently,
point mutations in the β-tubulin gene, predominantly in
exon 4, were associated with resistance to paclitaxel [10-
12]. Resistance to cisplatin was linked with anomalies in
the DNA MMR system resulting in microsatellite instabil-
ity (MSI) [13-16]. In order to evaluate the relevance of
these mechanisms to ovarian cancer chemoresistance, we
screened TUBB exon 4 for mutations and performed MSI
analysis in 34 ovarian carcinomas treated with paclitaxel/
cisplatin and evaluated patients' response to
chemotherapy.
Methods
Patient data
Thirty-four primary ovarian carcinoma patients, of serous
(26 cases) or clear cell (eight cases) histological types
(invasive or borderline), consecutively admitted at the
Portuguese Oncology Institute – Porto and treated with
the adjuvant chemotherapy scheme paclitaxel/cisplatin,
were analysed. Patients previously treated with other
chemotherapeutic regimens or radiotherapy were
excluded from the study.
Evaluation of treatment responses was done by an oncol-
ogist using computerized tomography or magnetic reso-
nance and CA125 quantification, according to
international guidelines [17]. Investigators performing
laboratory analysis were not aware of chemotherapy
response or resistance until the study was completed.
DNA extraction
Genomic DNA was extracted from chemo-naïve, paraffin
embedded tumours, after dissection. Tissue blocks were
sectioned, mounted on glass slides, deparaffinised, and
stained with haematoxylin and eosin. Tumour areas were
identified under the microscope on each slide and
marked. Areas with at least 70% of cancer cells were iden-
tified on tissue sections. Selected paraffin blocks were sec-
tioned (5µm sections) and mounted in microscope slides.
Marked tumour areas were selected with a sterile razor
blade. Three sections of tissue were incubated in a solu-
tion of 10 mM Tris-HCl buffer (pH 8.0), 2.5 mM MgCl2,
50 mM KCl, 0.5% (p/v) Tween 20, and 1 mg/mL protein-
ase K for 48 hours at 55°C.
TUBB exon 4 sequencing
For polymerase chain reaction (PCR) assays, different sets
of oligonucleotides were designed to amplify specific
regions of TUBB exon 4 that code for the GTP and paclit-
axel binding sites. To assure that the amplicon was not a
pseudogene, the following intronic primer set was used in
the first round PCR: 5'AAG-GAG-ATA-CAT-CCG-AGG-
GAA-TT3' and 5'AAG-GTA-TTC-ATG-ATG-CGA3'. After
checking for first round PCR product in an agarose gel, a
1:10 dilution was used for nested PCRs with the following
primers: set 1, 5'AGA-GAG-CTG-TGA-CTG-CCT-G3' and
5'AAG-GTA-TTC-ATG-ATG-CGA3'; set 2, 5'GCT-CTG-
GAA-TGG-GCA-CTC3' and 5'CCG-TAG-GTT-GGT-TGT-
GGT-CA3'; set 3, 5'CGG-GGA-TCT-GAA-CCA-CCT-T3'
and 5'GAG-TGT-CAC-GGC-CTG-GAG-T3'. The PCR prod-
ucts were separated by electrophoresis in agarose gels
stained with ethidium bromide and analysed in a transi-
luminator. All DNA samples were analysed in an auto-
matic DNA sequencer ABI PRISM 310™ Genetic Analyser.
The sequences were compared with the genomic sequence
GenBank AF070600.
MSI evaluation
For microsatellite analysis, tumour DNA was amplified
with primers for two quasimonomorphic markers BAT 26
(5'GAG-TGT-CAC-GGC-CTG-GAG-T3'; 5'AAC-CAT-TCA-
ACA-TTT-TTA-ACC-C3') and BAT 34 (5'ACC-CTG-GAG-
GAT-TTC-ATC-TC3'; 5'AAC-AAA-GCG-AGA-CCC-AGT-
CT3') [18-20]. Fragments were analysed in an ABI PRISM
310™ Genetic Analyser.
Results
Twenty-two of the 34 ovarian cancers (64.7%) presented
residual tumour after surgery, seven of which (7/22;
31.8%) were shown to be chemoresistant (five serous and
two clear cell tumours) (Table 1).
Amplicons of 700 bp were observed for all cases after
amplification with the intronic primers (data not shown).
Nested PCR with primer sets 1–3 specific for TUBB exon 4
resulted in amplicons with 129, 254, and 201 bp, respec-
tively (Figure 1). Sequencing analysis of all 34 cases
showed no TUBB exon 4 mutations (Figure 2).
Microsatellite analysis with markers BAT 26 and BAT 34
(Figure 3) showed the normal pattern in all cases, so no
evidence for microsatellite instability was detected in this
series.BMC Cancer 2005, 5:101 http://www.biomedcentral.com/1471-2407/5/101
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Discussion
Tumour resistance to chemotherapy or disease relapses
resistant to further treatment after an initial response are
common events in current cytotoxic cancer treatment reg-
imens [5]. With regard to ovarian cancer chemotherapy,
the current major challenge is to understand why histo-
logically similar tumours behave so differently when
treated with the same chemotherapeutic regimen. The
action of a drug potentially depends on several mecha-
nisms, namely, metabolisation, access into the tumour
microenvironment, intracellular uptake, interaction with
the target, and subsequent signalling events [5]. It is there-
fore important to study the different molecular mecha-
nisms that can be involved in chemotherapy resistance.
The rationale for studying the relationship between TUBB
gene mutations with paclitaxel resistance came from the
studies of Giannakakou et al and Gonzalez-Garay et al
[10,11], who found TUBB mutations in ovarian cancer
cell lines and in hamster cells, respectively. Subsequently,
Monzó et al [12] reported TUBB mutations in 16 out of 36
(44.4%) paclitaxel resistant tumour samples from
patients with advanced non-small cell lung cancer and
proposed that TUBB mutations could represent a possible
mechanism of paclitaxel resistance in that tumour type.
However, our findings in the present study argue against a
significant role of TUBB  gene mutations in paclitaxel
resistance in ovarian cancer. In keeping with our results,
Table 1: Clinical, pathological and genetic data of 34 ovarian cancer patients.
Patient Histological 
type
Stage Grade Residual 
tumour
Treatment 
response
Exon 4 TUBB 
mutation
MSI status
1 Serous III 1 > 2 cm CR Not present Stable
2 Serous III 2 < 2 cm CR Not present Stable
3 Serous III 3 > 2 cm CR Not present Stable
4 Serous III 1 > 2 cm WR Not present Stable
5 Serous III 2 > 2 cm CR Not present Stable
6 Serous III 2 < 2 cm CR Not present Stable
7 Serous III 3 > 2 cm CR Not present Stable
8 Serous III 3 > 2 cm CR Not present Stable
9 Serous III 3 > 2 cm CR Not present Stable
10 Serous III 3 > 2 cm CR Not present Stable
11 Serous III 3 > 2 cm CR Not present Stable
12 Serous III 3 > 2 cm WR Not present Stable
13 Serous III 3 > 2 cm WR Not present Stable
14 Serous IV 3 > 2 cm PR Not present Stable
15 Serous IV 3 > 2 cm CR Not present Stable
16 Serous IV 3 > 2 cm WR Not present Stable
17 Serous IV 3 > 2 cm WR Not present Stable
18 Serous IV 3 < 2 cm CR Not present Stable
19 Serous I 1 Absent - Not present Stable
20 Serous II 3 Absent - Not present Stable
21 Serous III 1 Absent - Not present Stable
22 Serous III 3 Absent - Not present Stable
23 Serous III 1 Absent - Not present Stable
24 Serous II B Absent - Not present Stable
25 Serous II B Absent - Not present Stable
26 Serous III B Absent - Not present Stable
27 Clear cell I 3 < 2 cm CR Not present Stable
28 Clear cell II 3 > 2 cm WR Not present Stable
29 Clear cell III 3 > 2 cm PR Not present Stable
30 Clear cell IV 3 > 2 cm WR Not present Stable
31 Clear cell I 3 Absent - Not present Stable
32 Clear cell I 3 Absent - Not present Stable
33 Clear cell II 3 Absent - Not present Stable
34 Clear cell III 3 Absent - Not present Stable
B: borderline tumours; CR: complete response; PR: partial response; WR: without response. The stage classification was according to the Federation 
Internationale de Gynecologie [21] and grading was defined as well differentiated (1), moderately differentiated (2), and poorly differentiated (3).BMC Cancer 2005, 5:101 http://www.biomedcentral.com/1471-2407/5/101
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Sale et al [22] and Lamendola et al [23] did not detect
TUBB gene mutations in ovarian cancer samples. Similar
findings have recently been obtained for several other
tumour types, namely, lung [24], breast [25,26], and gas-
tric cancer [27]. Taken together, our and several other
investigations concur that TUBB exon 4 mutations are not
an important mechanism underlying paclitaxel resistance.
To explain the early findings of Monzó et al [12], which
were not reproduced by other authors, including the
present study, Kelley et al [24] suggested that the primers
used by Monzó et al [12] did not allow to discriminate
TUBB from its pseudogenes [24]. Furthermore, the first
studies reporting TUBB  gene mutations were made in
hamster cells [11] and in ovarian cancer cell lines [10]
after selection by paclitaxel exposure, something that
makes difficult a direct extrapolation of these findings to
human tumours.
We have also evaluated the MSI status of the 34 ovarian
carcinomas with quasimonomorphic BAT 26 and BAT 34
markers, but did not find any microsatellite unstable
tumours. Some authors have described an association
between cisplatin resistance and MMR system anomalies
in ovarian adenocarcinomas [28-30], as well as in colon
cancer cell lines [31-33]. Additionally, other studies found
MSI in ovarian cancer, namely, in serous and clear cell his-
tological types [34-40]. However, the frequency of MSI
identified in those studies was quite low (0–14.3%),
which is in agreement with our findings. To completely
rule out any relationship between deficient mismatch
repair and cisplatin resistance, one would have to analyse
more microsatellite markers in a larger series of tumours
paired with normal DNA.
Conclusion
We conclude that, contrarily to earlier suggestions, TUBB
exon 4 mutations and MMR defects are not major mecha-
nisms underlying paclitaxel and/or cisplatin resistance in
ovarian cancer. Further investigation on alternative
mechanisms of resistance to these drugs is warranted. Pos-
sible mechanisms to paclitaxel resistance are P-glycoprotein
overexpression [5,41], differential β-tubulin isotype
expression [5,42,43], and apoptosis deregulation [5,44-
46]. Decrease in intracellular cisplatin level, increase of
tolerance or repair of DNA lesions, and alterations in the
Nested PCR products (in duplicate) obtained with the three  primer sets specific for TUBB exon 4 in an ovarian carcinoma  (from right to left, lane 1: 100 bp step ladder; lanes 2 and 3:  129 bp amplicon – set 1 primers; lanes 4 and 5: 254 bp ampli- con – set 2 primers; lanes 6 and 7: 201 bp amplicon – set 3  primers) Figure 1
Nested PCR products (in duplicate) obtained with the three 
primer sets specific for TUBB exon 4 in an ovarian carcinoma 
(from right to left, lane 1: 100 bp step ladder; lanes 2 and 3: 
129 bp amplicon – set 1 primers; lanes 4 and 5: 254 bp ampli-
con – set 2 primers; lanes 6 and 7: 201 bp amplicon – set 3 
primers).
Electrophorogram of part of TUBB exon 4 without any  sequence variation in an ovarian carcinoma Figure 2
Electrophorogram of part of TUBB exon 4 without any 
sequence variation in an ovarian carcinoma.
Electrophorograms of BAT 26 (A) and BAT 34 (B) markers  in an ovarian carcinoma, showing the same pattern found in  normal control DNA Figure 3
Electrophorograms of BAT 26 (A) and BAT 34 (B) markers 
in an ovarian carcinoma, showing the same pattern found in 
normal control DNA.BMC Cancer 2005, 5:101 http://www.biomedcentral.com/1471-2407/5/101
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apoptotic cascade have also been related with cisplatin
resistance [5,47]. These studies are necessary to predict
individual response of patients to these chemotherapeutic
agents.
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